Minneapolis Portfolio Management Group LLC Acquires 8,780 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Minneapolis Portfolio Management Group LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 272,894 shares of the medical equipment provider’s stock after purchasing an additional 8,780 shares during the quarter. Zimmer Biomet accounts for about 2.8% of Minneapolis Portfolio Management Group LLC’s portfolio, making the stock its 21st largest position. Minneapolis Portfolio Management Group LLC owned about 0.14% of Zimmer Biomet worth $24,539,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. New Mexico Educational Retirement Board lifted its position in Zimmer Biomet by 2.2% during the fourth quarter. New Mexico Educational Retirement Board now owns 9,122 shares of the medical equipment provider’s stock valued at $820,000 after purchasing an additional 200 shares during the last quarter. Main Management ETF Advisors LLC lifted its position in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after purchasing an additional 112 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its position in Zimmer Biomet by 0.5% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 65,366 shares of the medical equipment provider’s stock valued at $5,878,000 after purchasing an additional 352 shares during the last quarter. MUFG Securities EMEA plc lifted its position in Zimmer Biomet by 114.4% during the fourth quarter. MUFG Securities EMEA plc now owns 8,130 shares of the medical equipment provider’s stock valued at $731,000 after purchasing an additional 4,338 shares during the last quarter. Finally, Forsta AP Fonden lifted its position in Zimmer Biomet by 2.2% during the fourth quarter. Forsta AP Fonden now owns 36,400 shares of the medical equipment provider’s stock valued at $3,273,000 after purchasing an additional 800 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.6%

ZBH stock opened at $82.83 on Tuesday. The company has a market capitalization of $16.02 billion, a PE ratio of 21.51, a P/E/G ratio of 1.90 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The firm’s 50-day moving average is $87.82 and its 200 day moving average is $90.61. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Leerink Partners initiated coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They issued a “hold” rating and a $101.00 target price on the stock. UBS Group reissued a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $102.70.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.28% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.